When was Orgenesis founded?

Orgenesis was founded in 2008 and raised its 1st funding round 5 years after it was founded.

Where is Orgenesis located?

Orgenesis is headquartered in Germantown, United States. It is registered at Aye, Rue de la Science 8 6900 Marche-en-Famenne.

How many employees does Orgenesis have?

As of Aug 31, 2026, the latest employee count at Orgenesis is 37.

Is Orgenesis a funded company?

Orgenesis is a funded company, having raised an undisclosed amount across 11 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on May 13, 2013.

When was the latest funding round of Orgenesis?

Orgenesis' latest funding was a $***** Post IPO round on Mar 04, 2024, with participation from 0 investor.

What is the annual revenue of Orgenesis?

Annual revenue of Orgenesis is between $1M and $10M as on Dec 31, 2024

Where does Orgenesis rank among its competitors?

Orgenesis ranks 6th amongst 135 active competitors, of which 33 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Scarlet Therapeutics, which secured $3.77M in May, 2026.

Who are the top competitors of Orgenesis?

Orgenesis' top competitors include Enlivex Pharmaceuticals, Pluri and Mytos. Among them, Scarlet Therapeutics secured the most recent funding round in May, 2026.

Orgenesis - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of cell and gene therapies for multiple disorders. The pipeline drugs include ORGCAR19for Lymphoma, MOTC for melanoma, RanTop HPV for Genital Warts, Anal Dysplasia for covid-19, Kyslecel for chronic pancreatitis, Cartil-S for Osteoarthritis, and others.

Website: orgenesis.com
Registered Address: Aye, Rue de la Science 8 6900 Marche-en-Famenne

Key Metrics

Founded Year

2008

Location

Germantown, United States

Stage

Public

Latest Funding Round

Post IPO, Mar 04, 2024, $*****

Investors

Nathan Low & 5 more

Ranked

6^th among 135 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2024

Employee Count

37 as on Aug 31, 2026

Investment & Acquisitions

Octomera & 2 more

Similar Companies

Enlivex Pharmaceuticals & 42 more

Exit Details

Public

View Orgenesis' full profile

Orgenesis is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ORGENESIS SERVICES SRL CIN: 0790.353.624 , Belgium, Active	Sep 01, 2022	-	-	-
Orgenesis (Belgium) CIN: 0540.866.555 , Belgium, Active	Oct 16, 2013	-	-	-
Orgenesis Inc. CIN: 1460602 , United States, Active	Aug 09, 2021	$1M - $10M (As on Dec 31, 2024)	167 (As on Dec 31, 2022)	-

Orgenesis got listed on Jul 28, 2010.

Click here to take a look at Orgenesis's IPO in detail

Orgenesis has raised funding over 11 rounds. Its first funding round was on May 13, 2013. Orgenesis has 5 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Orgenesis:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 04, 2024	3814380	Post IPO	1872776	3938073	4576575	8485558
May 11, 2023	3742142	Post IPO	6198571	1116923	3164654	Metalmark Capital
Nov 2022	4812363	Post IPO	2799175	7350225	8475867	Metalmark Capital

Access funding benchmarks and valuations. Sign up today!

View details of Orgenesis's funding rounds and investors

Orgenesis' employee count trend

Orgenesis has 37 employees as of Aug 26. Here is Orgenesis's employee count trend over the years:

Uncover Orgenesis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Orgenesis include Enlivex Pharmaceuticals, Pluri and Mytos. Here is the list of Top 10 competitors of Orgenesis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Enlivex Pharmaceuticals 2005, Jerusalem (Israel), Public	Developer of autologous and allogeneic cell immunotherapy therapy treatments	$7M	Pontifax, Korea Investment Holdings & 2 others	62/100
2nd	Pluri 2003, Haifa (Israel), Public	Developer of three-dimensional cell expansion platforms for various industries	-	Merchant Adventure Investment Advisors, Europa ... & 2 others	61/100
3rd	Mytos 2016, London (United Kingdom), Series A	Provider of automated cell manufacturing for regenerative medicine applications	$19M	Buckley Ventures, Wing Venture Capital & 6 others	58/100
4th	Oxford BioMedica 1995, Oxford (United Kingdom), Public	Manufacturer of viral vectors for cell and gene therapy products	-	Oberland Capital, Vitruvian Partners & 7 others	58/100
5th	Sernova 1998, London (Canada), Public	Regenerative medicine to deliver proteins and hormones for disease treatment	-	National Research Council Canada, Evotec & 1 others	57/100
6th	Orgenesis 2008, Germantown (United States), Public	Developer of cell and gene therapies for multiple disorders	-	Metalmark Capital, Boundary & 4 others	55/100
7th	TissueGene 1999, Rockville (United States), Series C	Developer of regenerative therapies for orthopedic diseases	$94.6M	Q Capital Partners, Maryland Stem Cell Research Fund ... Read more	55/100
8th	Vital Therapies 2003, San Diego (United States), Public	Developer of cell-based therapy to treat acute liver failure	$216M	Versant Ventures, Gershon Capital & 8 others	53/100
9th	Cellvie 2020, Houston (United States), Seed	Developer of cell-derived therapeutics solutions for the treatment of cardiac health, stroke & kidney transplantation	$15.5M	Taiho Ventures, Kizoo & 2 others	52/100
10th	Scarlet Therapeutics 2022, Bristol (United Kingdom), Series A	Developer of cell-based therapeutics to treat a wide range of diseases	$7.09M	SCVC, Meltwind Advisory & 6 others	52/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Orgenesis's competitors? Click here to see the top ones

Orgenesis has made 1 investment in Octomera and acquired Tissue Genesis and Koligo Therapeutics.

Here is the list of these investments and acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jan 31, 2024	Investments	Octomera	2022	United States
Oct 19, 2020	Acquisition	Tissue Genesis	2001	Honolulu (United States)
Sep 29, 2020	Acquisition	Koligo Therapeutics	2016	Louisville (United States)